Generics Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA), the world's leading generics firm, reported results for the quarter ended March 31, 2011, in line with forecasts and showing that sales were up 12% at $4.1 billion, boosted by strong growth in Europe, and non-GAAP net income and non-GAAP earnings per share of $936 million and $1.04, up 13% and 14%, respectively. Quarterly GAAP net income was $761 million, up 7%; GAAP EPS totaled $0.84, up 6%. 12 May 2011